Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, Double-Blinded, Controlled Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency (iCHF-2)
2015-005744-34Phase 4Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ferric carboxymaltose in myocardial infarction (MI), cardiac morbidity and iron deficiency anemia (IDA) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Change in left ventricular ejection fraction in AMI cohort. Started Sep 2018; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
myocardial infarction (MI)cardiac morbidityiron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2015-005744-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005744-34.